comparemela.com
Home
Live Updates
BRIGHTSTAR: Local Consolidative Therapy with Brigatinib in Tyrosine Kinase Inhibitor-Naïve ALK-Rearranged Metastatic NSCLC : comparemela.com
BRIGHTSTAR: Local Consolidative Therapy with Brigatinib in Tyrosine Kinase Inhibitor-Naïve ALK-Rearranged Metastatic NSCLC
Expert oncologist Yasir Elamin, MD, shares data from the BRIGHTSTAR trial and considers how it may inform real-world use of brigatinib in patient with ALK-rearranged metastatic non–small cell lung cancer.
Related Keywords
Yasir Elamin ,
,
Local Consolidative Therapy ,
Tyrosine Kinase Inhibitor Na ,
Rearranged Metastatic ,
Nsclc ,
Non Small Cell Lung Cancer ,
Lung Cancer ,
Metastatic Nsclc ,
Metastatic Lung Cancer ,
Brightstar Trial ,
Brightstar Study ,
Brigatinib ,
Tyrosine Kinase Inhibitor ,
Tyrosine Kinase Inhibition ,
Study Design ,
Trial Design ,
Patient Characteristics ,
Efficacy Data ,
Safety Data ,
Flct ,
Consolidation Therapy ,
Pfs Data ,
Progression Free Survival ,
comparemela.com © 2020. All Rights Reserved.